C&EN White Paper
Emerging drug discovery strategies for targeted protein degradation
Brought to you by WuXi AppTec

Targeted protein degradation can be used to achieve efficacy in various disease contexts where other therapies fail. PROTACs® are unique, high-molecular-weight compounds that facilitate the labeling of a target protein, marking it for removal by cellular degradation machinery. These molecules bring two proteins together, and action dependent on the formation of a three-part complex introduces challenges during drug discovery and development.

Learn how to identify PROTAC candidates using DNA-encoded libraries and explore specialized screening and analytical techniques for target validation, compound optimization, mechanistic studies, and in vivo testing.

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Key Objectives:
  • PROTACs® are an emerging treatment modality with promise for treating a range of diseases.
  • DNA-encoded libraries are well suited for the screening and identification of PROTACs.
  • PROTACs are high molecular weight compounds with unique mechanisms of action that require careful preparation and analysis.

Brought to you by:
WuXi AppTec
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2023 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy